Clearing the Air on Residual Solvents - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Clearing the Air on Residual Solvents
USP 9467: Residual Solvents will take effect on July 1, 2008. But does the industry understand these specifications—and is it prepared?


Pharmaceutical Technology


This means that excipient companies will need to share a lot more information about their process and their material residual levels than they had previously. "Some small pharma companies and generics houses haven't really talked to their suppliers about how these materials are made," says Schoneker. "These companies then have to scramble to get better information from their suppliers than they had done in the past."

The problem that arises is that companies tend to develop exhaustive, sometimes irrelevant, questionnaires for their suppliers. "Suppliers are getting different questionnaires from every customer and asking different questions—some are reasonable and some about issues that don't really matter," says Schoneker. "You have to have this balance. How do you share information in a reasonable way so that you get what you need without putting the excipient supplier in a situation where they are having to do a huge amount of work to supply their customers with information they consider confidential?"

IPEC is working on excipient qualification guidelines, which focus on technical and GMP qualification and information and understanding how much information companies need to meet the requirements. IPEC's Excipient Information Protocol has a section on residual solvents and discusses the need for the supplier to incorporate the key information that is needed to use the material and meet the residual solvents guideline.

The effect on OTC manufacturers. Some over-the-counter (OTC) products also may fall under the USP ‹467› requirements. "A lot of these issues are always positioned in terms of Rx-type products, but there is a whole other business area that often gets overlooked," says Tine Engel, PhD, principal scientist at The Procter & Gamble Company (Mason, OH). In general, OTCs contain a lot more excipients and ingredients because consumers are interested in taste, mouth feel, and so forth, which require additional nontherapeutic ingredients in formulations.

OTC products with USP monographs fall under the requirements in USP ‹467›. Other OTCs may be approved under an NDA or ANDA but do not have a USP monograph. "In these cases, we will probably continue to apply the ICH Q3C guideline," says Ouderkirk.

Engel and other OTC analysts largely support the USP ‹467› changes. "I think they are good rules. The fact that USP has harmonized with ICH means we don't have to make up different rules for products that we sell at different global locations. What people may not realize is that we are working with a lot of different materials and at bigger quantities. It takes more raw materials to make a tube of toothpaste than a pill. And we do have to be very careful to set up good systems because normally consumers are more exposed to many of our products. You may take a pill once a day, but you brush your teeth two or three times a day. Any additional testing that is required hits us doubly hard. Of course it is very important to protect the safety of the consumer, but we need to do it in a way that isn't going to put OTC companies out of business."

Retesting concerns. Manufacturers that choose not to pay close attention to the requirements may undergo costly consequences. "One of the things we see almost every time a USP revision comes out is that there is always a group of products that have been tested according to an older version of USP, and then if they don't immediately employ their (raw) material in the manufacture and it sits in a warehouse while the USP changes, they all of a sudden are stuck in a situation where they are trying to use material that is now out of spec," says Dr. Jon Brice. If a manufacturer tests its raw material according to a USP monograph, uses it in manufacture and then USP changes, the company is grandfathered in. However, if a company tests its raw material and then the material sits in storage and during that time the USP changes, then they simply can't use that material in manufacturing because the company must test according to the USP that is in effect when manufacture begins and must retest.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here